Neuro-Oncology Advances : Impact Factor & More
eISSN: 2632-2498
Open AccessShare this on:
Key Metrics
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Neuro-Oncology Advances
Neuro-Oncology Advances Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | Oxford University Press |
| Language | English |
| Article Processing Charges | GBP 1500 | USD 2206 |
| Publication Time | 12 |
| Editorial Review Process | Peer review |
| General Details | |
| Publication Details | |
| Publication Time | 12 |
| Waiver Policy | Visit website |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Neuro-Oncology Advances ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Neuro-Oncology Advances
TLSB-27\u2003INTRACRANIAL ACTIVITY OF DATOPOTAMAB DERUXTECAN IN PATIENT-DERIVED MODELS OF BREAST CANCER BRAIN METASTASES
- 7 Aug 2026
- Neuro-Oncology Advances
MMDA-01\u2003LEPTOMENINGEAL DISEASE IN ALK-POSITIVE NSCLC: SURVIVAL IMPACT OF THIRD-GENERATION ALK INHIBITORS
- 7 Aug 2026
- Neuro-Oncology Advances
SADA-11\u2003A SCOPING REVIEW OF NUTRITIONAL STATUS IN THE CARE OF PATIENTS WITH METASTATIC SPINE DISEASE
- 7 Aug 2026
- Neuro-Oncology Advances
MMDA-09\u2003PROGNOSTIC DIFFERENCE BETWEEN HOMOGENEOUS VS. HETEROGENEOUS INTRACRANIAL RESPONSE OF MELANOMA BRAIN METASTASES TO IPILIMUMAB AND NIVOLUMAB
- 7 Aug 2026
- Neuro-Oncology Advances
RTAD-05\u2003LOCAL RECURRENCE AND RADIONECROSIS WITH 3-FRACTION STEREOTACTIC RADIOTHERAPY FOR POSTOPERATIVE CAVITIES AND INTACT BRAIN METASTASES: A PROSPECTIVE REGISTRY STUDY
- 7 Aug 2026
- Neuro-Oncology Advances
CLTR-01\u2003SURGICAL SELECTION PATTERNS IN NSCLC BRAIN METASTASES: CLINICAL AND MOLECULAR CORRELATES IN THE TKI ERA
- 7 Aug 2026
- Neuro-Oncology Advances
TLSB-27\u2003INTRACRANIAL ACTIVITY OF DATOPOTAMAB DERUXTECAN IN PATIENT-DERIVED MODELS OF BREAST CANCER BRAIN METASTASES
- 7 Aug 2026
- Neuro-Oncology Advances
MMDA-01\u2003LEPTOMENINGEAL DISEASE IN ALK-POSITIVE NSCLC: SURVIVAL IMPACT OF THIRD-GENERATION ALK INHIBITORS
- 7 Aug 2026
- Neuro-Oncology Advances
SADA-11\u2003A SCOPING REVIEW OF NUTRITIONAL STATUS IN THE CARE OF PATIENTS WITH METASTATIC SPINE DISEASE
- 7 Aug 2026
- Neuro-Oncology Advances
MMDA-09\u2003PROGNOSTIC DIFFERENCE BETWEEN HOMOGENEOUS VS. HETEROGENEOUS INTRACRANIAL RESPONSE OF MELANOMA BRAIN METASTASES TO IPILIMUMAB AND NIVOLUMAB
- 7 Aug 2026
- Neuro-Oncology Advances
RTAD-05\u2003LOCAL RECURRENCE AND RADIONECROSIS WITH 3-FRACTION STEREOTACTIC RADIOTHERAPY FOR POSTOPERATIVE CAVITIES AND INTACT BRAIN METASTASES: A PROSPECTIVE REGISTRY STUDY
- 7 Aug 2026
- Neuro-Oncology Advances
CLTR-01\u2003SURGICAL SELECTION PATTERNS IN NSCLC BRAIN METASTASES: CLINICAL AND MOLECULAR CORRELATES IN THE TKI ERA
- 7 Aug 2026
- Neuro-Oncology Advances
FAQs on Neuro-Oncology Advances
How many articles did Neuro-Oncology Advances publish last year? 
Who is the publisher of Neuro-Oncology Advances?
